Skip to main content
. 2016 Mar 16;7(17):23785–23800. doi: 10.18632/oncotarget.8122

Figure 4. LL-37 induces PI3K-dependent TRPV2 translocation to pseudopodia membranes.

Figure 4

(A) Immunofluorescence analysis on non-permeabilized cells revealing the translocation of TRPV2 to the plasma membrane by (L)-LL-37 and (D)-LL-37 peptides and blocked by PI3K inhibitor LY2940042 (1 μM). (B) Localisation of TRPV2 by immunoelectron microscopy. The location of immunogold signals, intracellularly and sporadically at pseudopodia (P) before and accumulated at pseudopodia after 5 min of cell treatment with LL-37, is indicated with arrows.